BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 15700398)

  • 21. Tenofovir: what have over 1 million years of patient experience taught us?
    Pozniak A
    Int J Clin Pract; 2008 Aug; 62(8):1285-93. PubMed ID: 18705824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No change in calculated creatinine clearance after tenofovir initiation among Thai patients.
    Gayet-Ageron A; Ananworanich J; Jupimai T; Chetchotisakd P; Prasithsirikul W; Ubolyam S; Le Braz M; Ruxrungtham K; Rooney JF; Hirschel B;
    J Antimicrob Chemother; 2007 May; 59(5):1034-7. PubMed ID: 17376791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.
    Muñoz de Benito RM; Arribas López JR
    Expert Rev Anti Infect Ther; 2006 Aug; 4(4):523-35. PubMed ID: 17009933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
    Hsu R; Lanier ER; Rouse EG; Oie KL; Pappa KA; Ross LL
    Antivir Ther; 2008; 13(5):735-7. PubMed ID: 18771059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
    Dominguez S; Ghosn J; Peytavin G; Izzedine H; Wirden M; Ktorza N; Miller M; Aubron-Olivier C; Trylesinski A; Calvez V; Deray G; Katlama C
    J Med Virol; 2007 Feb; 79(2):105-10. PubMed ID: 17177308
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A; McAllister J; Amin J; Cooper DA; Carr A
    HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention.
    Shoptaw S; Rotheram-Fuller E; Landovitz RJ; Wang J; Moe A; Kanouse DE; Reback C
    AIDS Care; 2008 Mar; 20(3):376-81. PubMed ID: 17963091
    [No Abstract]   [Full Text] [Related]  

  • 28. Boosted Reyataz comparable to Kaletra.
    AIDS Patient Care STDS; 2005 Jan; 19(1):60. PubMed ID: 15700399
    [No Abstract]   [Full Text] [Related]  

  • 29. [Complete HAART in a single pill. New milestone for improving compliance].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():40-1. PubMed ID: 19024916
    [No Abstract]   [Full Text] [Related]  

  • 30. Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
    Mocroft A; Phillips AN; Ledergerber B; Katlama C; Chiesi A; Goebel FD; Knysz B; Antunes F; Reiss P; Lundgren JD
    AIDS; 2006 May; 20(8):1141-50. PubMed ID: 16691065
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDA makes final approvals.
    AIDS Patient Care STDS; 2006 May; 20(5):381. PubMed ID: 16758553
    [No Abstract]   [Full Text] [Related]  

  • 32. Tenofovir/probenecid combination in HIV/HBV-coinfected patients: how to escape Fanconi syndrome recurrence?
    Izzedine H; Thibault V; Valantin MA; Peytavin G; Schneider L; Benhamou Y
    AIDS; 2010 Apr; 24(7):1078-9. PubMed ID: 20386378
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial comment: mixing tenofovir with other nephrotoxins--how safe is this?
    Gupta SK
    AIDS Read; 2009; 19(6):246. PubMed ID: 19642244
    [No Abstract]   [Full Text] [Related]  

  • 34. Adverse events experienced by three children taking tenofovir and didanosine in combination.
    Hawkins S; Ball C
    HIV Med; 2007 Sep; 8(6):411. PubMed ID: 17661851
    [No Abstract]   [Full Text] [Related]  

  • 35. Improvements in parameters of end-stage liver disease in patients with HIV/HBV-related cirrhosis treated with tenofovir.
    Matthews GV; Cooper DA; Dore GJ
    Antivir Ther; 2007; 12(1):119-22. PubMed ID: 17503756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Once-daily Kaletra approved.
    AIDS Patient Care STDS; 2005 Jul; 19(7):467. PubMed ID: 16053404
    [No Abstract]   [Full Text] [Related]  

  • 37. Two drugs in one pill.
    Vazquez E
    Posit Aware; 1997; 8(6):19. PubMed ID: 11364854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What you need to know about Combivir.
    AIDS Alert; 1998 Jan; 13(1):suppl 1. PubMed ID: 11364867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tipranavir favored in RESIST-2.
    AIDS Patient Care STDS; 2005 Jan; 19(1):59. PubMed ID: 15700396
    [No Abstract]   [Full Text] [Related]  

  • 40. RESIST-1 results released.
    AIDS Patient Care STDS; 2005 Jan; 19(1):58-9. PubMed ID: 15665636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.